| HER2-low breast cancer: pathological and clinical landscape P Tarantino, E Hamilton, SM Tolaney, J Cortes, S Morganti, E Ferraro, ... Journal of Clinical Oncology 38 (17), 1951-1962, 2020 | 471 | 2020 |
| Next generation sequencing (NGS): a revolutionary technology in pharmacogenomics and personalized medicine in cancer S Morganti, P Tarantino, E Ferraro, P D’Amico, BA Duso, G Curigliano Translational research and onco-omics applications in the era of cancer …, 2019 | 179 | 2019 |
| Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies P Tarantino, R Carmagnani Pestana, C Corti, S Modi, A Bardia, ... CA: a cancer journal for clinicians 72 (2), 165-182, 2022 | 171 | 2022 |
| Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life S Morganti, P Tarantino, E Ferraro, P D’Amico, G Viale, D Trapani, ... Critical reviews in oncology/hematology 133, 171-182, 2019 | 124 | 2019 |
| Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer P Tarantino, Q Jin, N Tayob, RM Jeselsohn, SJ Schnitt, J Vincuilla, ... JAMA oncology 8 (8), 1177-1183, 2022 | 116 | 2022 |
| Evolution of low HER2 expression between early and advanced-stage breast cancer P Tarantino, S Gandini, E Nicolò, P Trillo, F Giugliano, P Zagami, ... European Journal of Cancer 163, 35-43, 2022 | 103 | 2022 |
| Immunotherapy for early triple negative breast cancer: research agenda for the next decade P Tarantino, C Corti, P Schmid, J Cortes, EA Mittendorf, H Rugo, ... NPJ Breast Cancer 8 (1), 23, 2022 | 83 | 2022 |
| The risk of coronary artery disease and cerebrovascular disease in patients with hepatitis C: A systematic review and meta-analysis P Ambrosino, R Lupoli, A Di Minno, L Tarantino, G Spadarella, ... International journal of cardiology 221, 746-754, 2016 | 77 | 2016 |
| Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review P Tarantino, S Modi, SM Tolaney, J Cortés, EP Hamilton, SB Kim, M Toi, ... JAMA oncology 7 (12), 1873-1881, 2021 | 74 | 2021 |
| SARS-CoV-2 vaccines for cancer patients: a call to action C Corti, E Crimini, P Tarantino, G Pravettoni, AMM Eggermont, S Delaloge, ... European Journal of Cancer 148, 316-327, 2021 | 72 | 2021 |
| Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives E Nicolò, F Giugliano, L Ascione, P Tarantino, C Corti, SM Tolaney, ... Cancer Treatment Reviews 106, 102395, 2022 | 66 | 2022 |
| Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials P Tarantino, S Gandini, D Trapani, C Criscitiello, G Curigliano Critical reviews in oncology/hematology 159, 103223, 2021 | 62 | 2021 |
| ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer P Tarantino, G Viale, MF Press, X Hu, F Penault-Llorca, A Bardia, ... Annals of Oncology 34 (8), 645-659, 2023 | 61 | 2023 |
| Percutaneous electrochemotherapy in the treatment of portal vein tumor thrombosis at hepatic hilum in patients with hepatocellular carcinoma in cirrhosis: A feasibility study L Tarantino, G Busto, A Nasto, R Fristachi, L Cacace, M Talamo, ... World Journal of Gastroenterology 23 (5), 906, 2017 | 61 | 2017 |
| Therapeutic cancer vaccines revamping: technology advancements and pitfalls G Antonarelli, C Corti, P Tarantino, L Ascione, J Cortes, P Romero, ... Annals of Oncology 32 (12), 1537-1551, 2021 | 48 | 2021 |
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial SM Tolaney, P Tarantino, N Graham, N Tayob, L Parè, G Villacampa, ... The Lancet Oncology 24 (3), 273-285, 2023 | 45 | 2023 |
| Bystander effect of antibody–drug conjugates: fact or fiction? F Giugliano, C Corti, P Tarantino, F Michelini, G Curigliano Current oncology reports 24 (7), 809-817, 2022 | 45 | 2022 |
| Optimizing the safety of antibody–drug conjugates for patients with solid tumours P Tarantino, B Ricciuti, SM Pradhan, SM Tolaney Nature reviews Clinical oncology 20 (8), 558-576, 2023 | 40 | 2023 |
| Cardiovascular risk markers in patients with primary aldosteronism: a systematic review and meta-analysis of literature studies P Ambrosino, R Lupoli, A Tortora, M Cacciapuoti, GA Lupoli, P Tarantino, ... International Journal of Cardiology 208, 46-55, 2016 | 37 | 2016 |
| Navigating the HER2-low paradigm in breast oncology: new standards, future horizons P Tarantino, G Curigliano, SM Tolaney Cancer Discovery 12 (9), 2026-2030, 2022 | 35 | 2022 |
